Journal of Bioequivalence & Bioavailability

Parenteral drug delivery systems for insoluble drugs

7^th World Congress on Bioavailability & Bioequivalence: BA/BE Studies Summit

August 29-31, 2016 Atlanta, USA

Jim Jingjun Huang

Ascendia Pharmaceuticals, USA

Keynote: J Bioequiv Availab

Abstract:

Poor water solubility of more than 60-80% of new chemical entity present a major hurdles in the design of suitable drug delivery systems for the market dosage form. Administration of those compounds by parenteral route without causing injection site reaction and systemic toxicity effects constitutes another barrier. Current solubilization and parenteral delivery technologies for water insoluble drug are summarized. The key considerations in design of stable parenteral drug delivery system, such as drug physico-chemical and biopharmaceutical properties, selection and evaluation of solubilization and delivery technology, and excipients are presented. Case studies in development of nanoemulsions and nanosuspension are presented.

Biography :

Jim Jingjun Huang has Founded Ascendia Pharmaceuticals in the year 2012 after 15 years of Pharmaceutical R&D and Management experience at Pfizer, Baxter, AstraZeneca and Roche. He has led the formulation development efforts for the successful transition of several oral and parenteral dosage forms from discovery through formulation, manufacturing, technical transfer and ultimately commercialization. He holds a PhD in Pharmaceutics from the University of the Sciences in Philadelphia (formerly Philadelphia College of Pharmacy and Sciences) where he worked with Joseph B Schwartz. His research interests are centered on improvement of solubility and dissolution, and controlled delivery of poorly water soluble drugs through Nano-emulsion and Amorphous Solid Dispersion Technologies. He has been a Reviewer for the Journal of Pharmaceutical Sciences, International Journal of Pharmaceutics, Journal of Controlled Release, Drug Development and Industrial Pharmacy, PDA Journal of Pharmaceutical Science and Technology, Molecular Pharmaceutics and Pharmaceutical Research. Currently, he is a Member of American Association of Pharmaceutical Scientists (AAPS) and American Chemical Society (ACS).

Email: j.huang@ascendiapharma.com